An independent data safety monitoring committee (DSMC) has given DiscGenics the go-ahead to enroll the final 24 patients in its first-in-human U.S. clinical study of IDCT.
DiscGenics to Present at 2019 Musculoskeletal New Ventures Conference
DiscGenics Announces Publication of Preclinical Data for Disc Degeneration Treatment in The Spine Journal
DiscGenics’ U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark
DiscGenics Receives FDA Fast Track Designation for Cell Therapy for Disc Degeneration
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DiscGenics’ investigational cell therapy, IDCT, currently being evaluated in regulator-allowed clinical trials in the U.S. and Japan for the reduction in pain and disability associated with degenerative disc disease (DDD), a major cause of chronic low back pain.
DiscGenics Announces First Patients Treated in Japanese Clinical Trial of Cell Therapy for Degenerative Disc Disease
First Utahns Treated in Nationwide FDA-Allowed Clinical Study of Locally Developed Cell Therapy for Chronic Low Back Pain
DiscGenics Congratulates Chief Medical Officer, Dr. Kevin T. Foley, on Receiving the 2019 AANS Cushing Award for Technical Excellence and Innovation in Neurosurgery
Chief Medical Officer, Kevin T. Foley, MD, FACS, FAANS was awarded the 2019 AANS Cushing Award for Technical Excellence and Innovation in Neurosurgery. The award honors an AANS member for technical prowess and skill and/or innovation in the development of new procedures that have become part of the arsenal a neurosurgeon uses to treat disease or trauma.
Local Bio-tech and Regenerative Medicine Company Expands in Salt Lake City
DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease
DiscGenics Receives Approval from Japanese Pharmaceuticals and Medical Devices Agency to Begin Clinical Evaluation of Non-Surgical Degenerative Disc Disease Treatment in Japan
DiscGenics to Present at 2018 Cell & Gene Meeting on the Mesa
New Cell Therapy Could Help Millions Suffering from Back Pain
CTI Clinical Trial and Consulting Services Announces Collaboration with DiscGenics on First-In-Human Trial of Cell Therapy IDCT for Degenerative Disc Disease
DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease
DiscGenics Presents Promising Preclinical Study Results at ORS 2018
Cryoport to Provide DiscGenics with Cutting Edge Cold Chain Logistics Support for its Phase 1/2 Trial
DiscGenics Joins MedCision’s ThawSTAR Early Adopter Program for Cell Therapy Clinical Trials
MedCision, LLC, the world leader in next-generation automated cell thawing for advanced therapies, and DiscGenics, Inc., a regenerative medicine company focused on developing cell therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that DiscGenics has joined MedCision’s ThawSTAR Clinical Early Adopter Program.
DiscGenics Receives FDA Allowance of IND to Commence Clinical Study of Its Degenerative Disc Disease Therapy
DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, is pleased to announce that it has been notified by the U.S. Food and Drug Administration (FDA) that an Investigational New Drug (IND) Application for a clinical study of its first product candidate, IDCT, may proceed.
DiscGenics Raises $14 Million in Series B Financing
DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has closed a $14 million Series B financing.